Siren, L.L.C. Black Diamond Therapeutics, Inc. Transaction History
Siren, L.L.C.
- $2.26 Trillion
- Q4 2024
A detailed history of Siren, L.L.C. transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Siren, L.L.C. holds 1,046,517 shares of BDTX stock, worth $2.48 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
1,046,517
Previous 1,046,517
-0.0%
Holding current value
$2.48 Million
Previous $4.55 Billion
50.8%
% of portfolio
0.1%
Previous 0.23%
Shares
1 transactions
Others Institutions Holding BDTX
# of Institutions
94Shares Held
47.6MCall Options Held
2.9KPut Options Held
69.4K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.5MShares$24.8 Million0.01% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$20.2 Million0.36% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$13.3 Million0.71% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$10.5 Million0.68% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$7.62 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $86.1M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...